Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality

ISSN： 1776-2596

Source： Targeted Oncology, Vol.5, Iss.4, 2010-12, pp. : 229-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pathology and personalized medicine in lung cancer

By Kerr Keith M Loo Peh Sun Nicolson Marianne C

Lung Cancer Management, Vol. 2, Iss. 1, 2013-02 ,pp. : 35-46

Future Medicine

Access to resources Recommend Favorite

Personalized, Precision Lung Cancer Medicine through Integrated Genomic Analysis

By Bivona Trever G.

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 43-49

Optimal Clinical Ltd

Access to resources Recommend Favorite

Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma

Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Iss. 3, 2013-09 ,pp. : 319-334

Bentham Science Publishers

Access to resources Recommend Favorite

Biomathematics in the development of personalized medicine in oncology

By Agur Zvia

Future Oncology, Vol. 2, Iss. 1, 2006-02 ,pp. : 39-42

Future Medicine

Access to resources Recommend Favorite

New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD1839) and other innovative therapies

By Goss G.

EJC Supplements, Vol. 1, Iss. 8, 2003-10 ,pp. : 1-1

Elsevier

Access to resources Recommend Favorite